Gefitinib, a pharmacological inhibitor of EGFR inhibits growth and invasion of urothelial cell lines in which erbB1 is constitutively activated

被引：0
|
作者：
Nicole, G
Vordos, D
Daher, A
Maillé, P
Bakkar, A
Pages, C
Jouault, H
Abbou, CC
de Medina, SGD
Chopin, DK
机构：
来源：
JOURNAL OF UROLOGY | 2005年 / 173卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(18)34818-3
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
578
引用
收藏
页码：158 / 158
页数：1
相关论文
共 46 条
  • [1] Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation
    Nicolle, G
    Daher, A
    Maillé, P
    Vermey, M
    Loric, S
    Bakkar, A
    Wallerand, H
    Vordos, D
    Vacherot, F
    de Medina, SGD
    Abbou, CC
    Van der Kwast, T
    Thiery, JP
    Radvanyi, F
    Chopin, DK
    CLINICAL CANCER RESEARCH, 2006, 12 (09) : 2937 - 2943
  • [2] Growth inhibitory effects and mechanisms of lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosine kinase, in gastric cell lines
    Kim, J. W.
    Im, S. A.
    Kim, H. P.
    Oh, D. Y.
    Kim, T. Y.
    Bang, Y. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 262 - 262
  • [3] POPDC1 inhibits breast cancer cell migration and proliferation, and is regulated by EGFR (ErbB1) and cAMP
    Amunjela, Johanna N.
    Tucker, Steven J.
    CANCER RESEARCH, 2017, 77
  • [4] BCRP expression is functionally upregulated by epidermal growth factor receptor (EGFR, ErbB1) mediated signaling in human ovarian cancer cell lines, but not in human breast cancer cell lines
    Nakanishi, Takeo
    Shiozawa, Ken
    Hamburger, Anne W.
    Ross, Douglas D.
    CANCER RESEARCH, 2006, 66 (08)
  • [5] Simultaneous inhibition of ErbB1 and ErbB2 signaling significantly enhances the growth suppression of rat and human cholangiocarcinoma cell lines
    Zhang, Zichen
    Sirica, Alphonse Eugene
    FASEB JOURNAL, 2007, 21 (05): : A71 - A72
  • [6] A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo
    Xu, Ruodan
    Povlsen, Gro Klitgaard
    Soroka, Vladislav
    Bock, Elisabeth
    Berezin, Vladimir
    CELLULAR ONCOLOGY, 2010, 32 (04) : 259 - 274
  • [7] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
    Anderson, NG
    Ahmad, T
    Chan, K
    Dobson, R
    Bundred, NJ
    INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782
  • [8] Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
    Erjala, Kaisa
    Sundvall, Maria
    Junttila, Teemu T.
    Zhang, Na
    Savisalo, Mika
    Mali, Pekka
    Kulmaia, Jarmo
    Pulkkinen, Jaakko
    Grenman, Reidar
    Elenius, Klaus
    CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4103 - 4111
  • [9] A new class of protein cancer biomarker candidates: Differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines
    Omenn, Gilbert S.
    Guan, Yuanfang
    Menon, Rajasree
    JOURNAL OF PROTEOMICS, 2014, 107 : 103 - 112
  • [10] Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2, and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 Expression
    Marshall, G.
    Klinowska, T. C. M.
    Mills, E. A.
    Ogilvie, D.
    Hickinson, D. M.
    Speake, G.
    CANCER RESEARCH, 2009, 69 (24) : 784S - 785S
12345